AdheriumADRMD 8 10-Year RORE % is -10.71 as of Dec. 2025. GuruFocus rates ADRMD with a GF Score™ of 8/100 and a GF Value™ of $0.53. The stock has 8 warning signs investors should review. Among 429 Medical Devices & Instruments companies, Adherium ranks worse than 71.33% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Adherium's 10-Year RORE % for the quarter that ended in Dec. 2025 was -10.71%.
The industry rank for Adherium's 10-Year RORE % or its related term are showing as below:
ADRMD's 10-Year RORE % is ranked worse than 71.33% of 429
companies
in the Medical Devices & Instruments industry
Industry Median: 0.6
vs ADRMD: -10.71
Adherium (OTCPK:ADRMD) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Adherium 10-Year RORE % Related Terms
Adherium 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Adherium's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Adherium's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adherium 10-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adherium's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Adherium's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.
Adherium (ADRMD) has a 10-Year RORE % of -10.71 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Adherium and its competitors. According to the industry distribution chart, Adherium ranks #306 out of 429 companies in the Medical Devices & Instruments industry, placing it in the top 71.3%.
Is Adherium's 10-Year RORE % too high?
Adherium's current 10-Year RORE % is -10.71. Based on the distribution chart, Adherium ranks #306 out of 429 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Adherium has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Adherium's 10-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Adherium ranks #306 out of 429 companies for 10-Year RORE %. This places Adherium in the lower half of its industry. The industry median 10-Year RORE % is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 0.60, based on 429 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Adherium and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adherium's current 10-Year RORE % is -10.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adherium stock overvalued right now?
Adherium (ADRMD) has a current 10-Year RORE % of -10.71. The stock's GF Value™ is $0.53, compared to a current price of $0.30 — trading 43.4% below its estimated fair value. The current 10-Year RORE % is -10.71. Adherium's overall GF Score™ is 8/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Adherium (ADRMD), the current 10-Year RORE % is -10.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adherium (ADRMD) Overvalued in 2026?
Based on GuruFocus' analysis, Adherium stock appears to be undervalued.
The current stock price of $0.30 is trading 43.4% below its estimated GF Value™ of $0.53.
Key valuation signals for ADRMD:
10-Year RORE %: -10.71
GF Value™: $0.53 vs. price of $0.30 (43.4% below fair value)
No single metric tells the full story. See the ADRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. It is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. Its geographically segments include New Zealand and Australia, Europe, North America, and Asia. The majority of its revenue comes from Europe.
8GF Score
Get the complete analysis for ADRMD
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADRMD has been successfully added to your 
